Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-26-059422
Filing Date
2026-05-12
Accepted
2026-05-12 16:20:46
Documents
80
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q rzlt-20260331x10q.htm   iXBRL 10-Q 1545872
2 EX-31.1 rzlt-20260331xex31d1.htm EX-31.1 15245
3 EX-31.2 rzlt-20260331xex31d2.htm EX-31.2 15237
4 EX-32.1 rzlt-20260331xex32d1.htm EX-32.1 7284
5 EX-32.2 rzlt-20260331xex32d2.htm EX-32.2 7297
  Complete submission text file 0001104659-26-059422.txt   8138494

Data Files

Seq Description Document Type Size
6 EX-101.SCH rzlt-20260331.xsd EX-101.SCH 55136
7 EX-101.CAL rzlt-20260331_cal.xml EX-101.CAL 39267
8 EX-101.DEF rzlt-20260331_def.xml EX-101.DEF 266952
9 EX-101.LAB rzlt-20260331_lab.xml EX-101.LAB 484739
10 EX-101.PRE rzlt-20260331_pre.xml EX-101.PRE 413017
84 EXTRACTED XBRL INSTANCE DOCUMENT rzlt-20260331x10q_htm.xml XML 1572405
Mailing Address 275 SHORELINE DRIVE, SUITE 500 REDWOOD CITY CA 94065
Business Address 275 SHORELINE DRIVE, SUITE 500 REDWOOD CITY CA 94065 650-206-4507
Rezolute, Inc. (Filer) CIK: 0001509261 (see all company filings)

EIN.: 273440894 | State of Incorp.: NV | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 001-39683 | Film No.: 26968928
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)